Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion

Diabetologia

Volumn 52, Issue 5, 2009, Pages 873-881

  Mingrone, G ^a   Nolfe, G ^b   Castagneto Gissey, G ^c   Iaconelli, A ^a   Leccesi, L ^a   Guidone, C ^a   Nanni, G ^a   Holst, J J ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF KENT   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bariatric surgery; Circadian rhythm; GIP; GLP1; Morbid obesity

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BILIOPANCREATIC BYPASS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADULT; BILIOPANCREATIC DIVERSION; BLOOD GLUCOSE; BODY MASS INDEX; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCRETINS; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; OBESITY, MORBID;

EID: 64149110845     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-009-1288-9     Document Type: Article

References (29)

1. T Vilsbøll JJ Holst 2004 Incretins, insulin secretion and type 2 diabetes mellitus Diabetologia 47 357 366
2. M Nauck MM Heimesaat C Orskov JJ Holst R Ebert W Creutzfeldt 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin Invest 91 301 307
3. M Nauck F Stöckmann R Ebert W Creutzfeldt 1986 Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 29 46 52
4. P Zimmet KG Alberti J Shaw 2001 Global and societal implications of the diabetes epidemic Nature 414 782 787
5. CL Leibson DF Williamson LJ Melton 3rd 2001 Temporal trends in BMI among adults with diabetes Diabetes Care 24 1584 1589
6. A Golay J Ybarra 2005 Link between obesity and type 2 diabetes Best Pract Res Clin Endocrinol Metab 19 649 663
7. E Muscelli A Mari A Casolaro 2008 Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients Diabetes 57 1340 1348
8. JW Anderson L Grant L Gotthelf LT Stifler 2006 Weight loss and long-term follow-up of severely obese individuals treated with an intense behavioral program Int J Obes 31 488 493
9. KG MacDonald SD Long MS Swanson 1997 The gastric bypass operation reduces the progression and mortality of NIDDM J Gastrointest Surg 1 213 220
10. F Rubino M Gagner P Gentileschi 2004 The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism Ann Surg 240 236 242
11. C Guidone M Manco E Valera-Mora 2006 Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery Diabetes 55 2025 2031
12. B Laferrère J Teixeira J McGinty 2008 Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes J Clin Endocrinol Metab 93 2479 2485
13. B Laferrère S Heshka K Wang 2007 Incretin levels and effect are markedly enhanced 1 month after roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes Diabetes Care 30 1709 1716
14. F Rodieux V Giusti DA D'Alessio M Suter L Tappy 2008 Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release Obesity 16 298 305
15. WJ Pories RJ Albrecht 2001 Etiology of type II diabetes mellitus: role of the foregut World J Surg 25 527 531
16. G Mingrone A DeGaetano AV Greco 1997 Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids Diabetologia 40 599 605
17. S Camastra M Manco A Mari 2007 Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery Diabetes Care 30 1002 1004
18. A Mari M Manco C Guidone 2006 Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function Diabetologia 49 2136 2143
19. RA DeFronzo JD Tobin R Andres 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance Am J Physiol 237 E214 E223
20. T Krarup S Madsbad AJ Moody 1983 Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type I (insulin dependent) diabetics J Clin Endocrinol Metab 56 1306 1312
21. C Rskov L Rabenhøj H Kofod A Wettergren JJ Holst 1994 Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man Diabetes 43 535 539
22. C Simon G Brandenberger 2002 Ultradian oscillations of insulin secretion in humans Diabetes 51 S258 S261
23. PR Flatt CJ Bailey P Kwasowski T Page V Marks 1984 Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice J Endocrinol 101 249 256
24. T Vilsbøll T Krarup J Sonne 2003 Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus J Clin Endocrinol Metab 88 2706 2713
25. PL McClean N Irwin RS Cassidy JJ Holst VA Gault PR Flatt 2007 GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet Am J Physiol Endocrinol Metab 293 E1746 E1755
26. VA Gault N Irwin BD Green 2005 Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes Diabetes 54 2436 2446
27. AB Damholt H Kofod AM Buchan 1999 Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine Cell Tissue Res 298 287 293
28. PL McClean N Irwin K Hunter VA Gault PR Flatt 2008 (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy Br J Pharmacol 155 690 701
29. F Rubino 2008 Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis Diabetes Care 31 S290 S296